Trials / Completed
CompletedNCT01298518
A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients
A Phase 1B, Randomized, Double-Blind, Placebo-Controlled Trial To Assess The Efficacy And Safety Of 4-Week Administration Of Multiple Oral Doses Of PF-04620110 In Type 2 Diabetes Mellitus Subjects With Insufficient Glycemic Control On Metformin
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the safety and tolerability, and pharmacodynamics, of multiple oral doses of PF-04620110 in T2DM patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-04620110 | 5 mg of PF-04620110 given once daily |
| DRUG | PF-04620110 | 2.5 mg of PF-04620110 given twice daily |
| DRUG | Placebo | Matching placebo giving for 4 weeks |
Timeline
- Start date
- 2011-02-01
- Primary completion
- 2011-05-01
- Completion
- 2011-05-01
- First posted
- 2011-02-17
- Last updated
- 2012-11-06
- Results posted
- 2012-11-06
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01298518. Inclusion in this directory is not an endorsement.